RESUMO
OBJECTIVES: To evaluate the occurrence of relapse of multibacillary leprosy after multi-drug treatment including daily rifampin. METHODS: A retrospective review was performed utilizing data from the National Hansen's Disease Program (NHDP) on patients with leprosy treated and followed from 1988-1997 who received multi-drug therapy including daily rifampin. The occurrence of relapse in this cohort was measured, and demographic data and various clinical variables were also gathered. RESULTS: Ultimately, 158 cases fulfilled the eligibility criteria. 77% of cases were multibacillary patients and were treated with 2 or 3 drug protocols at rates of 36% and 35% before and after 1992, respectively. Only one case of relapse was found, and this patient underwent 2-drug therapy versus 3-drug therapy. CONCLUSION: These data are remarkable for the absence of relapse with daily rifampin, as contrasted with the published experience using the WHO protocol with monthly rifampin.
Assuntos
Hansenostáticos/administração & dosagem , Hanseníase/tratamento farmacológico , Rifampina/administração & dosagem , Administração Cutânea , Administração Oral , Adulto , Idoso , Biópsia , Clofazimina/administração & dosagem , Dapsona/administração & dosagem , Esquema de Medicação , Quimioterapia Combinada , Feminino , Seguimentos , Inquéritos Epidemiológicos , Humanos , Hanseníase/epidemiologia , Hanseníase/patologia , Hanseníase/prevenção & controle , Masculino , Prontuários Médicos , Pessoa de Meia-Idade , Estudos Retrospectivos , Prevenção Secundária , Resultado do Tratamento , Estados Unidos/epidemiologiaRESUMO
A patient with Hansen's disease received corticosteroids for a type 1 leprosy reaction and subsequently developed a new cutaneous lesion at the original biopsy site from which Mycobacterium fortuitum was cultured. A review of the literature found only two other cases of coinfection with atypical mycobacteria and Mycobacterium leprae, although there are many reports of pulmonary tuberculosis in patients with leprosy. This case highlights the diagnostic difficulties encountered when a patient has two different mycobacterial infections of the skin. The published experience emphasizes that such coinfection is remarkably uncommon in leprosy, despite the frequent use of high doses of corticosteroids for leprosy reactions.